Effect of matrix metalloproteinase-9 inhibitors in hepatitis B virus replication
DOI:
https://doi.org/10.13181/mji.oa.257895Keywords:
hepatitis B, IFNAR1, interferon beta, matrix metalloproteinase-9Abstract
BACKGROUND Hepatitis B virus (HBV) remains difficult to eradicate due to the persistence of covalently closed circular DNA (cccDNA). Matrix metalloproteinase-9 (MMP-9) enhances HBV replication, but the effects of its inhibition remain unexplored. This study aimed to investigate the effects of MMP-9 inhibitors on HBV replication markers.
METHODS Primary hepatocyte cultures were obtained from the livers of 6 Tupaia javanica. Cultures were infected with HBV from human sera and divided into control and intervention groups. The intervention group received MMP-9 inhibitors at 1, 3, and 7 nM. The control group received phosphate-buffered saline. Levels of hepatitis B surface antigen (HBsAg), HBV DNA, cccDNA, MMP-9, interferon alpha and beta receptor subunit 1 (IFNAR1), and interferon beta (IFN-β) were measured in both groups before and 72 hours post-intervention.
RESULTS MMP-9 inhibitor administration at 1, 3, and 7 nM consistently reduced HBsAg, HBV DNA, cccDNA, and MMP-9 levels, though not statistically significant. Median HBV DNA levels at 1, 3, and 7 nM were 7.05, 5.29, and 5.98 ×103 copies/ml, respectively. Mean cccDNA levels at 1, 3, and 7 nM were 14.15, 11.04, and 13.94 ×103 copies/ml, respectively. The 3 nM dose increased IFNAR1 levels, while the 7 nM dose increased IFN-β, but neither change was significant. Among the tested doses, 3 nM showed the most favorable effects despite the lack of significance.
CONCLUSIONS MMP-9 inhibitor suppressed HBsAg, HBV DNA, cccDNA, and MMP-9 while increasing IFNAR1 and IFN-β in vitro.
Downloads
References
World Health Organization. Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024.
Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2(7):163-86. https://doi.org/10.20517/2394-5079.2016.05
Coffin CS, Mulrooney-Cousins PM, Peters MG, van Marle G, Roberts JP, Michalak TI, et al. Molecular characterization of intrahepatic and extrahepatic hepatitis B virus (HBV) reservoirs in patients on suppressive antiviral therapy. J Viral Hepat. 2011;18(6):415-23. https://doi.org/10.1111/j.1365-2893.2010.01321.x
Stoll-Becker S, Repp R, Glebe D, Schaefer S, Kreuder J, Kann M, et al. Transcription of hepatitis B virus in peripheral blood mononuclear cells from persistently infected patients. J Virol. 1997;71(7):5399-407. https://doi.org/10.1128/jvi.71.7.5399-5407.1997
İnan N, Tabak F. Hepatitis B virus: biology and life cycle. Viral Hepat J. 2015;21(1):1-7. https://doi.org/10.4274/vhd.36036
De Andrea M, Ravera R, Gioia D, Marisa G, Landolfo S. The interferon system: an overview. Eur J Paediatr Neurol. 2002;6 Suppl A:A41-6. https://doi.org/10.1053/ejpn.2002.0573
Lee S, Baldridge MT. Interferon-Lambda: a potent regulator of intestinal viral infections. Front Immunol. 2017;8:749. https://doi.org/10.3389/fimmu.2017.00749
Lin FC, Young HA. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 2014 Aug;25(4):369-76. https://doi.org/10.1016/j.cytogfr.2014.07.015
Li Y, Liu H, Xu L. Expression of MMP-9 in different degrees of chronic hepatitis B and its correlation with inflammation. Exp Ther Med. 2018;16:4136-40. https://doi.org/10.3892/etm.2018.6673
Chen J, Xu W, Chen Y, Xie X, Zhang Y, Ma C, et al. Matrix metalloproteinase 9 facilitates hepatitis B virus replication through binding with type I interferon (IFN) receptor 1 to repress IFN/JAK/STAT signaling. J Virol. 2017;91(8):e01824-16. https://doi.org/10.1128/JVI.01824-16
Li J, Shi TD, Han JF, Zeng XG, Fan CL, Han C, et al. A systematic study of Tupaia as a model for human acute hepatitis B infection. J Vet Med Sci. 2021;83(6):1004-11. https://doi.org/10.1292/jvms.21-0026
Surya M, Iskandriati D, Sajuthi D, Pamungkas J. Development of Tupaia javanica Immortal Hepatocytes Culture for Javan Gibbon Hepatitis B Virus Replication. Int J Sci Basic Appl Res. 2016;28(1):44-52.
Surya M, Iskandriati D, Mariya S, Saepuloh U, Permanawati, Sajuthi D, et al. Primary Tupaia javanica hepatocytes cultures as in vitro replication system for ape hepatitis B viruses. Microbiol Indones. 2016;10(2):57-64. https://doi.org/10.5454/mi.10.2.3
Kalista KF, Surya M, Mariya S, Iskandriati D, Hasan I, Gani RA. Primary Tupaia javanica hepatocyte culture as an in vitro model for human hepatitis B virus infection. J Gastroenterol Hepatol Dig Endosc. 2021;22(3):203-9. https://doi.org/10.24871/2232021203-209
Ye J, Chen J. Interferon and hepatitis B: current and future perspectives. Front Immunol. 2021;12:733364. https://doi.org/10.3389/fimmu.2021.733364
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Kemal Fariz Kalista, Kuntjoro Harimurti, Suzanna Immanuel, Diah Iskandriati, Cosmas Rinaldi Adithya Lesmana, Fera Ibrahim, Rino Alvani Gani
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.
